Utility of overnight pulse oximetry and heart rate variability analysis to screen for sleep-disordered breathing in chronic heart failure

Neil R Ward, Martin R Cowie, Stuart D Rosen, Vitor Roldao, Manuel De Villa, Theresa A McDonagh, Anita Simonds, Mary J Morrell

ABSTRACT

Background Sleep-disordered breathing (SDB) is under diagnosed in chronic heart failure (CHF). Screening with simple monitors may increase detection of SDB in a cardiology setting. This study aimed to evaluate the accuracy of heart rate variability analysis and overnight pulse oximetry for diagnosis of SDB in patients with CHF.

Methods 180 patients with CHF underwent simultaneous polysomnography, ambulatory electrocardiography and wrist-worn overnight pulse oximetry. SDB was defined as an apnoea-hypopnoea index ≥15/h. To identify SDB from the screening tests, the per cent very low frequency increment (%VLFI) component of heart rate variability was measured with a pre-specified cutoff ≥2.23%, and the 3% oxygen desaturation index was measured with a pre-specified cutoff >7.5 desaturations/h.

Results 173 patients with CHF had adequate sleep study data; SDB occurred in 77 (45%) patients. Heart rate variability was measurable in 78 (45%) patients with area under the %VLFI receiver operating characteristic curve of 0.50. At the ≥2.23% cutoff, %VLFI sensitivity was 58% and specificity was 48%. The 3% oxygen desaturation index was measurable in 171 (99%) patients with area under the curve of 0.92. At the pre-specified cutoff of >7.5 desaturations/h, the 3% oxygen desaturation index had a sensitivity of 97%, specificity of 32%, negative likelihood ratio of 0.08 and positive likelihood ratio of 1.42. Diagnostic accuracy was increased using a cutoff of 12.5 desaturations/h, with sensitivity of 93% and specificity of 73%.

Conclusions The high sensitivity and low negative likelihood ratio of the 3% oxygen desaturation index indicates that pulse oximetry would be of use as a simple screening test to rule out SDB in patients with CHF in a cardiology setting. The %VLFI component of heart rate variability is not suitable for detection of SDB in CHF.

INTRODUCTION

Sleep-disordered breathing (SDB) occurs in ≥50% of patients with chronic heart failure (CHF) and despite an independent association with increased mortality, it is under diagnosed. Identification of patients with CHF who have SDB is complicated by the absence of classic symptoms such as excessive daytime sleepiness. Additionally, polysomnography is recommended for the diagnosis of SDB in CHF but these patients are often seen in cardiology clinics and access to this investigation may be limited. There is a need for simpler methods to enable the screening of patients with CHF for SDB.

Portable monitors such as overnight pulse oximetry have been used to diagnose obstructive sleep apnoea (OSA) in otherwise healthy adults but their utility in patients with comorbid medical conditions is unclear. A recent international workshop report has highlighted the need for further research to evaluate the role of portable monitors in patients with SDB and CHF.

We have previously shown in a small study that analysis of heart rate variability (HRV) can be used to rule out SDB in patients with CHF. HRV analysis can be performed during cardiological assessment and is potentially a convenient method to screen for SDB in CHF. The primary aim of this study was to prospectively evaluate the diagnostic performance of HRV analysis to detect SDB in a large number of patients with CHF in a general cardiology setting. HRV analysis may not be possible in patients with cardiac arrhythmias or paced cardiac rhythm and our secondary aim was to evaluate pulse oximetry as a screening strategy for patients with CHF who are unsuitable for HRV analysis. The following hypotheses were tested:
HRV analysis can be used to rule out SDB in patients with CHF; overnight pulse oximetry can be used to rule out SDB in patients with CHF and atrial fibrillation, paced cardiac rhythm, frequent ectopic beats or artefact on ambulatory ECG monitoring; HRV analysis has a higher accuracy than overnight pulse oximetry for the diagnosis of SDB in CHF.

Some of the results of this study have previously been presented in abstract form.\(^{11\,\text{a}}\)\(^{12\,\text{a}}\)

**METHODS**

Patients with low or preserved ejection fraction heart failure were recruited from cardiology outpatient clinics. Inclusion criteria required a diagnosis of CHF in accordance with European guidelines,\(^{13\,\text{a}}\) no hospitalisation or change in medication for \(\geq 4\) weeks and age 18–90 years. Patients receiving treatment for SDB were excluded. Eligible patients were invited to participate irrespective of clinical suspicion of SDB.

All patients underwent unattended polysomnography (SOMNOscreen, SOMNOMedics, Randersacker, Germany) with additional simultaneous recording with ambulatory electrocardiography (VistaPlus, Novacor, Rueil Malmaison Cedex, France) and wrist worn pulse oximetry (Pulsox Si, Konica Minolta, Tokyo, Japan) on the same night. Patients were studied in their own home or in hospital according to their preference. Anthropometric measurements and clinical interview were completed before the sleep study with a behavioural maintenance of wakefulness test (Oxford sleep resistance test (OSLER)) performed the next morning.\(^{14\,\text{a}}\) Full details of measurements are provided in the online supplement.

Polysomnography studies were analysed by one person unaware of the clinical status of the patient, using standard scoring criteria.\(^{15\,\text{a}}\) Apnoea was scored when nasal airflow reduced to \(< 10\%\) of baseline for \(\geq 10\) s. Hypopnoea was scored when nasal airflow reduced by \(\geq 50\%\) of baseline with a \(\geq 3\%\) oxygen desaturation and/or electroencephalographic arousal (see also online supplement). SDB was defined as an apnoea-hypopnoea index (AHI) \(\geq 15\) and was categorised as central sleep apnoea (CSA) or OSA.

The ambulatory ECG was recorded with a sampling frequency of 200 Hz. HRV was analysed (Holtersoft, Novacor) during the period from 00:00 to 06:00. Patients with paced cardiac rhythm, atrial fibrillation or \(>10\%\) ectopic beats were excluded from HRV analysis. Manual editing was performed to ensure all QRS complexes were correctly identified. The spectral density of the heart rate increment was analysed for measurement of the per cent very low frequency increment (%VLFI).\(^{16\,\text{a}}\) This component represents the very low frequency power (0.01–0.05 Hz) of the heart rate increment power expressed as the percentage of total power (0.01–0.5 Hz). An a priori %VLFI cut-off of \(\geq 2.23\%\) was used to diagnose SDB.\(^{10\,\text{a}}\) Recommended time domain and spectral components of HRV were also measured.\(^{17\,\text{a}}\)

The wrist worn pulse oximeter recorded oxygen saturation with a sampling time of 5 s and data storage frequency of 0.2 Hz. Overnight pulse oximetry was analysed (Download 2001, Stowood Scientific Instruments, Oxford, UK) for \(\geq 3\%\) oxygen desaturations during the ‘time in bed’ period recorded by the patient. The 3% oxygen desaturation index (3% ODI) was calculated as the mean number of \(\geq 3\%\) oxygen desaturations per hour, using the ‘time in bed’ as denominator. A pre-specified 3% ODI cutoff of \(> 7.5\) desaturations/h was used to diagnose SDB.

**Statistical analyses**

An a priori sample size of 180 patients with CHF was calculated to be adequately powered (1–\(\beta = 80\%\)) to detect a one-sided difference of \(>10\%\) between the sensitivity/specificity of HRV and polysomnography, at a significance level (\(\alpha\)) of 0.05 (see online supplement). Results are presented as median and IQR. Continuous variables were compared with Mann–Whitney or Kruskal–Wallis tests. Categorical variables were compared using Fisher’s exact test or \(\chi^2\) test. The diagnostic accuracy of the % VLFI and 3% ODI were compared by measurement of the area under the receiver-operating characteristic (ROC) curve. Sensitivity, specificity, predictive values and likelihood ratios for the %VLFI and 3% ODI were determined at the a priori cutoffs. Statistical analyses were performed using SPSS V.16.0.

**RESULTS**

Three hundred and fifty-four patients with CHF were identified who fulfilled the recruitment criteria, 180 of whom consented to participate (figure 1). One hundred and seventy-three patients with adequate polysomnography data were included in the analysis, with median age 69.8 (58.8–76.8) years and 86% were men (table 1). Most patients had mild to moderate symptomatic CHF with New York Heart Association class I or II symptoms in 77% and median left ventricle ejection fraction 40% (28–59%). One hundred and thirty-two (73%) patients had overnight monitoring performed in their home.

**Diagnosis of SDB from polysomnography**

The median AHI was 13.5 (7.2–24.8) events/h. SDB was diagnosed in 77 (45%) patients with CHF, with OSA in 55 (31%) and CSA in 24 (14%). As only a small number of patients had CSA, all patients with SDB were analysed as a single group. Body mass index, neck circumference and hip waist ratio were significantly higher in patients with CHF who had SDB.\(^{19\,\text{a}}\)
there were no significant differences in New York Heart Association class, brain natriuretic peptide or left ventricle ejection fraction among patients with and without SDB. Subjective and objective measures of sleepiness were similar irrespective of the presence or absence of SDB, but patients with SDB had significantly more stage 1 sleep and higher arousal index (table 3).

**Diagnostic accuracy of HRV**

HRV was measurable in 78 (45%) patients with CHF; the most common reasons for unsuitability for HRV measurement were pacemaker or atrial fibrillation (table 2). There were no significant differences in New York Heart Association class, brain natriuretic peptide or left ventricle ejection fraction among patients with and without SDB. Subjective and objective measures of sleepiness were similar irrespective of the presence or absence of SDB, but patients with SDB had significantly more stage 1 sleep and higher arousal index (table 3).

### Table 1  Clinical characteristics of patients with chronic heart failure (n=173)

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>71.9 (59.4–77.6)</td>
</tr>
<tr>
<td>Men (n, %)</td>
<td>81 (84)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.4 (24.8–31.6)</td>
</tr>
<tr>
<td>Neck size (cm)</td>
<td>39.0 (37.0–41.0)</td>
</tr>
<tr>
<td>Waist/hip ratio (%)</td>
<td>0.93 (0.96–0.99)</td>
</tr>
<tr>
<td>Diabetes (n, %)</td>
<td>22 (23)</td>
</tr>
<tr>
<td>COPD/asthma (n, %)</td>
<td>27 (28)</td>
</tr>
<tr>
<td>Ischaemic cardiomyopathy (n, %)</td>
<td>54 (56)</td>
</tr>
<tr>
<td>β blocker therapy (n, %)</td>
<td>62 (65)</td>
</tr>
<tr>
<td>ACEI/ARB therapy (n, %)</td>
<td>87 (91)</td>
</tr>
<tr>
<td>Atrial fibrillation (n, %)</td>
<td>26 (27)</td>
</tr>
<tr>
<td>Cardiac pacing (n, %)</td>
<td>25 (26)</td>
</tr>
<tr>
<td>NYHA classification (I/II/III/IV)</td>
<td>12/64/20/0</td>
</tr>
<tr>
<td>BNP (pg/ml)</td>
<td>128 (69–201)</td>
</tr>
<tr>
<td>Left ventricle ejection fraction (%)</td>
<td>40 (28–58)</td>
</tr>
</tbody>
</table>

Data are presented as median (IQR), or number (%) of patients.

ACEI/ARB, ACE inhibitor or angiotensin receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association.

### Table 2  Comparison of clinical characteristics in patients with chronic heart failure with and without sleep-disordered breathing

<table>
<thead>
<tr>
<th>Clinical characteristic</th>
<th>No SDB (n=96)</th>
<th>SDB (n=77)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>71.9 (59.4–77.6)</td>
<td>66.7 (57.1–75.0)</td>
<td>0.08</td>
</tr>
<tr>
<td>Men (n, %)</td>
<td>81 (84)</td>
<td>67 (87)</td>
<td>0.67</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>27.4 (24.8–31.6)</td>
<td>30.8 (27.8–35.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Neck size (cm)</td>
<td>39.0 (37.0–41.0)</td>
<td>42.0 (39.5–43.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Waist/hip ratio (%)</td>
<td>1.003 (0.96–1.05)</td>
<td>1.003 (0.99–1.07)</td>
<td>0.04</td>
</tr>
<tr>
<td>Diabetes (n, %)</td>
<td>22 (23)</td>
<td>22 (29)</td>
<td>0.48</td>
</tr>
<tr>
<td>COPD/asthma (n, %)</td>
<td>27 (28)</td>
<td>7 (9)</td>
<td>0.002</td>
</tr>
<tr>
<td>Ischaemic cardiomyopathy (n, %)</td>
<td>54 (56)</td>
<td>50 (59)</td>
<td></td>
</tr>
<tr>
<td>β blocker therapy (n, %)</td>
<td>62 (65)</td>
<td>64 (83)</td>
<td>0.009</td>
</tr>
<tr>
<td>ACEI/ARB therapy (n, %)</td>
<td>87 (91)</td>
<td>70 (91)</td>
<td>1.0</td>
</tr>
<tr>
<td>Atrial fibrillation (n, %)</td>
<td>26 (27)</td>
<td>26 (34)</td>
<td>0.41</td>
</tr>
<tr>
<td>Cardiac pacing (n, %)</td>
<td>25 (26)</td>
<td>26 (34)</td>
<td>0.32</td>
</tr>
<tr>
<td>NYHA classification (I/II/III/IV)</td>
<td>12/64/20/0</td>
<td>12/46/17/2</td>
<td>0.37</td>
</tr>
<tr>
<td>BNP (pg/ml)</td>
<td>128 (69–201)</td>
<td>107 (42–322)</td>
<td>0.97</td>
</tr>
<tr>
<td>Left ventricle ejection fraction (%)</td>
<td>40 (28–58)</td>
<td>43 (32–58)</td>
<td>0.76</td>
</tr>
</tbody>
</table>

Data are presented as median (IQR), or number (%) of patients.

ACEI/ARB, ACE inhibitor or angiotensin receptor blocker; BMI, body mass index; BNP, B-type natriuretic peptide; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; SDB, sleep-disordered breathing.

### Figure 2  Per cent very low frequency increment receiver-operating characteristic curve for diagnosis of sleep-disordered breathing (apnoea-hypopnoea index ≥15/h) in patients with chronic heart failure. AUC, area under curve.

![Figure 2](http://thorax.bmj.com/)

![AUC = 0.50](http://thorax.bmj.com/)
Sleep disordered breathing

![Figure 3](http://example.com/f3.png)

**Figure 3** Receiver-operating characteristic curves showing diagnostic accuracy of 3% oxygen desaturation index (3% ODI) for diagnosis of sleep-disordered breathing in (A) all patients with chronic heart failure (CHF) (n=171); (B) patients with CHF in whom %VLFI was not measurable (n=94); and (C) patients with CHF in whom %VLFI was measurable (n=77). AUC, area under curve.

2.32% (1.19–5.08), p=0.99). SDB was categorised as OSA in 31 (40%) patients with median %VLFI 2.35% (1.35–5.41); in 5 (6%) patients with CSA, median %VLFI was 0.78% (0.58–4.18). There was no significant difference between %VLFI in patients with CHF with OSA, CSA or without SDB (p=0.39).

The diagnostic accuracy of %VLFI was assessed using alternative AHI thresholds of $\geq 5$, $\geq 20$ and $\geq 50$ desaturations/h for diagnosis of SDB. The area under the %VLFI ROC curve was similar at all AHI thresholds with no significant change in sensitivity or specificity (table E2).

**Diagnosis accuracy of overnight pulse oximetry**

Overnight pulse oximetry could be analysed in 171 (99%) patients with CHF in whom %VLFI was present in 76 (44%). There was good agreement between 3% ODI and AHI (mean difference = $-0.2$ events/h; figure E1) with correlation coefficient (Spearman’s p) of 0.84 (figure E2). The 3% ODI had an area under the ROC curve of 0.92 (95% CI 0.88 to 0.96) for detection of SDB in CHF indicating high diagnostic accuracy (figure 3A). At the a priori cutoff of $>7.5$ desaturations/h for diagnosis of SDB in CHF, two false-negative results occurred with a sensitivity of 97% and negative likelihood ratio of 0.08 (table 4). However, at this cutoff there were 65 false-positive results with a specificity of 32% and a positive likelihood ratio of 1.42. In a post hoc analysis, a 3% ODI cutoff of $>12.5$ desaturations/h reduced the number of false-negative oximetry studies to 26, specificity increased to 75% (95% CI 64% to 81%), sensitivity was 93% (95% CI 86% to 97%) and negative likelihood ratio was 0.09 (95% CI 0.04 to 0.21).

To investigate the utility of overnight pulse oximetry for diagnosis of SDB in patients with CHF who were unsuitable for HRV analysis, the diagnostic accuracy of the 3% ODI was assessed in 94 patients in whom %VLFI was not measurable. In this subgroup, the 3% ODI had area under the ROC curve of 0.92 (95% CI 0.86 to 0.98; figure 3B). At the cutoff of $>7.5$ desaturations/h, the 3% ODI had a sensitivity of 98%, specificity of 24%, positive likelihood ratio of 1.28 and negative likelihood ratio of 0.10 for diagnosis of SDB in patients with CHF who were unsuitable for HRV analysis (table 4).

**Diagnostic accuracy of HRV analysis versus overnight pulse oximetry**

To compare HRV analysis and overnight pulse oximetry for detection of SDB in CHF, the diagnostic accuracy of the 3% ODI was assessed in 77 patients in whom %VLFI was measurable (table 4). In this subgroup, the 3% ODI had area under the ROC curve of 0.91 (95% CI 0.85 to 0.98; figure 3C) which was significantly greater than the value for %VLFI (p<0.0001).

**DISCUSSION**

The main findings of this study were that the %VLFI component of HRV was unable to discriminate between the presence and absence of SDB in patients with CHF. Moreover, it could be measured in less than half of the patients. In contrast, the 3%

---

**Table 4** Diagnostic accuracy of 3% oxygen desaturation index for detection of sleep-disordered breathing in patients with chronic heart failure

<table>
<thead>
<tr>
<th></th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Positive predictive value</th>
<th>Negative predictive value</th>
<th>Positive likelihood ratio</th>
<th>Negative likelihood ratio</th>
<th>Area under ROC curve</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients with CHF*  (n=171)</td>
<td>97 (91–100)</td>
<td>32 (22–41)</td>
<td>53 (45–62)</td>
<td>94 (79–99)</td>
<td>1.42 (1.24–1.64)</td>
<td>0.08 (0.02–0.34)</td>
<td>0.92 (0.88–0.96)</td>
</tr>
<tr>
<td>Patients with CHF without %VLFI measurement* (n=94)</td>
<td>98 (87–100)</td>
<td>24 (13–35)</td>
<td>49 (38–60)</td>
<td>93 (66–100)</td>
<td>1.28 (1.10–1.50)</td>
<td>0.10 (0.01–0.76)</td>
<td>0.92 (0.86–0.98)</td>
</tr>
<tr>
<td>Patients with CHF with %VLFI measurement* (n=77)</td>
<td>97 (85–100)</td>
<td>41 (28–57)</td>
<td>59 (47–72)</td>
<td>94 (73–100)</td>
<td>1.66 (1.28–2.16)</td>
<td>0.07 (0.01–0.48)</td>
<td>0.91 (0.85–0.98)</td>
</tr>
</tbody>
</table>

*Diagnostic accuracy values were assessed using the a priori cutoff of $>7.5$ desaturations/h for diagnosis of sleep-disordered breathing and are presented with 95% CI.

CHF, chronic heart failure; ROC, receiver operating characteristic; %VLFI, % very low frequency increment of heart rate variability.
O 2 desaturations/h, 3% ODI had high sensitivity with a clinically useful negative likelihood ratio of 0.08, and would therefore be of greatest clinical use to rule out SDB in CHF.

If overnight pulse oximetry was used as the initial investigation in a phased testing approach to detect SDB in CHF, further sleep studies would not have been required in 52 (53%) patients with CHF without SDB. However, at the cutoff of >7.5 desaturations/h, 3% ODI had poor specificity and low positive likelihood ratio. The diagnostic specificity of 3% ODI was increased at a cutoff of >12.5 desaturations/h without reduction in sensitivity. Using the 3% ODI cutoff of >12.5 desaturations/h would have correctly identified and saved further sleep studies in 69 (78%) patients with CHF without SDB.

A limitation of the present study is that paced cardiac rhythm or atrial fibrillation prevented HRV analysis in 43% of patients with CHF. While HRV may still be measurable in patients with cardiac resynchronisation therapy who are not atrial paced, and Cheyne-Stokes respiration can increase very low frequency HRV in patients with atrial fibrillation, the results of this study suggest that this would be of no value to screen for SDB in CHF. A second consideration is that we did not meet our desired sample size as HRV could not be analysed in all 180 patients with CHF recruited. However, further studies of the utility of %VLFI for diagnosis of SDB in CHF may not be an efficient use of resources; our results indicate a sample size of 780 patients with CHF suitable for HRV analysis would be required to be adequately powered to exclude a >0.5% difference in %VLFI between patients with and without SDB. A third consideration is that the small number of patients with CHF and CSA precluded comparison of the diagnostic accuracy of overnight pulse oximetry between patients with CSA and OSA. However, overnight oximetry has previously been reported to have 100% sensitivity for CSA in CHF, and in the current study, there were no false-negative oximetry results in patients with CSA.

A strength of this study is the recruitment of a heterogeneous population of patients with CHF from cardiology clinics, 34% of whom had an ejection fraction ≥50%. Many previous studies have only enrolled patients with low ejection fraction heart failure but up to 50% of patients with CHF have heart failure with preserved ejection fraction, and SDB may contribute to cardiac dysfunction in these patients. In addition, despite inclusion of patients with CHF and comorbidities including COPD and asthma which may influence overnight oxygen saturation, the diagnostic accuracy of the 3% ODI was high with area under the ROC curve of 0.92. However, this may have contributed to the low specificity of pulse oximetry at the cutoff of >7.5 desaturations/h.

In summary, in patients with CHF recruited from a cardiology setting, the 3% ODI cutoff of >7.5 desaturations/h had a high sensitivity of 97% and low negative likelihood ratio of 0.08 for diagnosis of SDB. Specificity of the 3% ODI was increased to 73% without reduction in sensitivity at an optimum 3% ODI cutoff of 12.5 desaturations/h. In contrast, the %VLFI had a poor diagnostic accuracy and it cannot be recommended to screen for SDB in patients with CHF. Overnight pulse oximetry would be of greatest clinical use to rule out SDB in patients with CHF, helping to reduce pressure on sleep laboratory facilities and prioritise patients who may require more detailed sleep studies.

Acknowledgements The authors are grateful to Dr B North and Dr E Kulinskaya of the Imperial College Statistical Advisory Service for providing statistical support for this study, and to Dr J Hooper of the Clinical Chemistry Department at the Royal Brompton Hospital for assistance with the BNP assay.
Sleep disordered breathing

Contributors MRC, SDR, AS, TAM, MJM: conceived the idea for this study, NRW, VR, MDV: data collection and analysis. NRW, MJM, AS, SDR, MRC: interpretation of data. NRW and MJM wrote the manuscript with critical input from SDR, AS and MRC.

Funding This study was funded by a grant from the British Heart Foundation and supported by the NHIR Respiratory Disease Biomedical Research Unit at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London. Ambulatory electrocardiography recorders and heart rate variability analysis software were provided on loan from the manufacturer, Novacoar, Paris, France.

Competing interests None.

Ethics approval Ethics approval was provided by Brompton, Harefield and NHLI Research Ethics Committee (COREC 07/0040/42/32).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data collected during this study are stored at the senior author’s institution.

REFERENCES


Utility of overnight pulse oximetry and heart rate variability analysis to screen for sleep-disordered breathing in chronic heart failure

Neil R Ward, Martin R Cowie, Stuart D Rosen, Vitor Roldao, Manuel De Villa, Theresa A McDonagh, Anita Simonds and Mary J Morrell

Thorax published online July 17, 2012

Updated information and services can be found at: http://thorax.bmj.com/content/early/2012/07/17/thoraxjnl-2012-201684

These include:

Supplementary Material
Supplementary material can be found at: http://thorax.bmj.com/content/suppl/2012/10/29/thoraxjnl-2012-201684.DC1

References
This article cites 37 articles, 9 of which you can access for free at: http://thorax.bmj.com/content/early/2012/07/17/thoraxjnl-2012-201684#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Screening (epidemiology) (366)
- Screening (public health) (366)
- Airway biology (1100)
- Sleep disorders (neurology) (199)
- Sleep disorders (respiratory medicine) (199)
- Sleep disorders (132)

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/